Immunoluminometric assay for copeptin measurement in cerebrospinal fluid: Technical aspects and pilot study.
Aneurysmal hemorrhage
Biomarker
Cerebrospinal fluid
Copeptin
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
24
05
2018
revised:
12
08
2018
accepted:
04
09
2018
pubmed:
9
9
2018
medline:
23
3
2019
entrez:
9
9
2018
Statut:
ppublish
Résumé
Copeptin acts as surrogate marker under stress stimuli, as well as an outcome predictor based on serum or plasma concentration in patients suffering intracranial hemorrhage, aneurysmal subarachnoid hemorrhage (aSAH), and stroke. The aim of this study was to establish a method for quantification of copeptin levels in cerebrospinal fluid (CSF) and to demonstrate its clinical applicability in patients following aSAH. This assay was validated for CSF samples using a commercial immunoluminometric assay (IMLA). For the control group (10 patients), CSF copeptin levels were determined in patients without signs of acute neurological diseases and who underwent a diagnostic lumbar puncture. The pilot cohort included calculation of copeptin levels in CSF and in serum of patients following aSAH. The control group had CSF copeptin levels lower than 0.78 pmol/L This assay provides to best of our knowledge for the first time initial ranges values of CSF copeptin for patients without acute neurological disease and in patients with aSAH. Thus, it opens new doors to develop further calculations and relationships between diseases biomarker and outcome prediction.
Sections du résumé
BACKGROUND
BACKGROUND
Copeptin acts as surrogate marker under stress stimuli, as well as an outcome predictor based on serum or plasma concentration in patients suffering intracranial hemorrhage, aneurysmal subarachnoid hemorrhage (aSAH), and stroke. The aim of this study was to establish a method for quantification of copeptin levels in cerebrospinal fluid (CSF) and to demonstrate its clinical applicability in patients following aSAH.
METHODS
METHODS
This assay was validated for CSF samples using a commercial immunoluminometric assay (IMLA). For the control group (10 patients), CSF copeptin levels were determined in patients without signs of acute neurological diseases and who underwent a diagnostic lumbar puncture. The pilot cohort included calculation of copeptin levels in CSF and in serum of patients following aSAH.
RESULTS
RESULTS
The control group had CSF copeptin levels lower than 0.78 pmol/L
CONCLUSIONS
CONCLUSIONS
This assay provides to best of our knowledge for the first time initial ranges values of CSF copeptin for patients without acute neurological disease and in patients with aSAH. Thus, it opens new doors to develop further calculations and relationships between diseases biomarker and outcome prediction.
Identifiants
pubmed: 30194934
pii: S0009-8981(18)30483-2
doi: 10.1016/j.cca.2018.09.005
pii:
doi:
Substances chimiques
Glycopeptides
0
copeptins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-185Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.